Notable Labs

Notable Labs Assets per Share

The Total Assets per Share of Notable Labs (NTBLQ) as of Nov 18, 2026 is 2.02 USD. In the previous year, Total Assets per Share was 3.07 USD — a change of -34.12% (lower).

Assets per Share

2.02USD

YoY

-34.12%

Last updated:

Total Assets per Share of Notable Labs is 2023 2.02 USD. Total Assets per Share of Notable Labs was 2022 3.07 USD. It decreases by -34.12% lower compared to the previous year.

The Notable Labs Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2016
4.89 USD
Jan 1, 2017
6.80 USD
Jan 1, 2018
6.28 USD
Jan 1, 2019
5.07 USD
Jan 1, 2020
4.32 USD
Jan 1, 2021
6.69 USD
Jan 1, 2022
3.07 USD
Jan 1, 2023
2.02 USD
The Notable Labs Assets per Share history
YEARAssets per ShareYoY
2.02USD-34.12%
3.07USD-54.13%
6.69USD+55.02%
4.32USD-14.89%
5.07USD-19.23%
6.28USD-7.63%
6.80USD+38.97%
4.89USD+20.46%
4.06USD+2.88%
3.95USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Total Assets per Share of Notable Labs is 2.02 USD in 2023.

Total Assets per Share of Notable Labs changed from 3.07 USD to 2.02 USD, representing a -34.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Notable Labs

All Key Metrics — Notable Labs